The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
HOME > BUSINESS
BUSINESS
- Abilify Posted US Sales of US$983 Mil. in Jul-Sep
October 31, 2011
- Anti-HIV JTK-303 Applied for Combination Tablet in the US: JT
October 31, 2011
- Losses Increase Due to Fallen Milestone Payments: OncoTherapy
October 31, 2011
- Wakamoto’s Apr-Sep Profits Up 2% on Latanoprost Sales Growth, Recovered Losses
October 31, 2011
- Terumo Posts Record Sales, Operating Profits in First Half FY2012
October 31, 2011
- PI Trial of Darinaparsin Inj. Starts for PTCL: Solasia
October 31, 2011
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
- Meiji Seika Pharma Planning to Develop Biosimilars for Infectious Diseases, Cancer, and RA
October 31, 2011
- Medipal HD: Near 90% Decline in Operating Profits
October 31, 2011
- Kyowa Kirin’s Pharmaceutical Business Reports Increases in Sales, Profits in Jan.-Sept. Driven by Nesp
October 28, 2011
- Novartis to Cut 2,000 Jobs in Manufacturing, Development Division
October 28, 2011
- Hisamitsu Forms Chinese Subsidiary to Enter OTC Business
October 28, 2011
- JDF, Eli Lilly Japan Create Subsidy Program for Basic Incretin Research
October 28, 2011
- Nitto Denko, Maruho Apply for Additional Indication for Penles Tape for Pain Relief with Removal of Warts
October 28, 2011
- Bayer to Continue to Discuss Filing for Approval for Regorafenib in Europe, US after Improvement of OS in PIII Trial
October 28, 2011
- Baxter's Worldwide Sales Up 10% to US$10.3 Bil. for 1st Nine Months of 2011
October 28, 2011
- Terumo: Record Sales, Operating Profits in 1st Half of FY2011
October 28, 2011
- Nexium Tops HP Market in September Led by 2 Active Marketers: RepTrack Survey
October 27, 2011
- DSP to Distribute iPad2 to All MRs from Jan. Next Year
October 27, 2011
- Takara Bio Upwardly Revises Profit Forecasts for 1st Half of FY2012
October 27, 2011
ページ
As Japan moves into elaborate discussions on the potential reform of its cost-effectiveness assessment (CEA) in FY2024, members of a…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
The Japanese government on September 12 approved Moderna’s updated monovalent COVID-19 vaccine directed at the Omicron XBB.1.5 strain, following its…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…